Company / Return on Assets (ROA)
CytomX Therapeutics, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
-11.5%
FY2025
5-year range
-38.1% / 26.4%
FY2021-FY2025
Trend
-143.3%
vs FY2024
Sector context
#85 of 213
Health Care
What the data says
At -11.5%, CytomX Therapeutics, Inc.'s return on assets (roa) ranks #85 of 213 in the Health Care sector. Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -38.1% in FY2022 to 26.4% in FY2024.
Based on SEC 10-K filings.
-11.5% in FY2025 with a 5-year CAGR of -2.3%.
Declined from -0.3% to -11.5% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +26.6pp
- 5-Year Change
- -2.3pp
- 10-Year Change
- -
Sector benchmark
#85 of 213 in Health CareTop 40% of 213This company -11.5% Sector average -24.1%
▼
+52.5% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 143.3% year-over-year.
- Currently 12.7pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2024.
- Lowest return on assets (roa) in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -11.5% | -143.3% |
| FY2024 | 26.4% | +9542.9% |
| FY2023 | -0.3% | +99.3% |
| FY2022 | -38.1% | -11.5% |
| FY2021 | -34.1% | -272.3% |
| FY2020 | -9.2% | +69.4% |
| FY2019 | -30.0% | -61.9% |
| FY2018 | -18.5% | -70.8% |
| FY2017 | -10.8% | +63.4% |
| FY2016 | -29.6% | -285.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026